Research map: Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences

Back to the article

Papers in this map

  1. How Many Interviews Are Enough? · Greg Guest · 2005 · 20699 citations · Cited by this paper
  2. Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Riddhi A. Babel · 2026 · Related
  3. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma · S. Vincent Rajkumar · 2014 · 5044 citations · Cited by this paper
  4. Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · 2026 · Related
  5. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness · Cathal Doyle · 2013 · 2502 citations · Cited by this paper
  6. Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · 2026 · Related
  7. Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force · John F. P. Bridges · 2011 · 2086 citations · Cited by this paper
  8. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · 2026 · Related
  9. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma · Robert A. Kyle · 2007 · 932 citations · Cited by this paper
  10. IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · 2026 · Related
  11. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma · Sagar Lonial · 2019 · 912 citations · Cited by this paper
  12. Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · 2026 · Related
  13. How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity · Matthew Quaife · 2018 · 382 citations · Cited by this paper
  14. Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · 2026 · Related
  15. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria · Arjun Lakshman · 2018 · 307 citations · Cited by this paper
  16. A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer · 2026 · Related
  17. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) · María‐Victoria Mateos · 2020 · 294 citations · Cited by this paper
  18. Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary · 2026 · Related
  19. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma · Meletios Athanasios Dimopoulos · 2024 · 120 citations · Cited by this paper
  20. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) · Ola Landgren · 2020 · 105 citations · Cited by this paper
  21. Prevalence of smoldering multiple myeloma based on nationwide screening · Sigrún Þorsteinsdóttir · 2023 · 94 citations · Cited by this paper
  22. Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review · Eline van Overbeeke · 2018 · 90 citations · Cited by this paper
  23. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study · Annie N. Cowan · 2023 · 87 citations · Cited by this paper
  24. Treatment for High-Risk Smoldering Myeloma · Sigurdur Yngvi Kristinsson · 2013 · 84 citations · Cited by this paper
  25. Prevalence, incidence and survival of smoldering multiple myeloma in the United States · Aishwarya Ravindran · 2016 · 74 citations · Cited by this paper
  26. Smoldering multiple myeloma current treatment algorithms · S. Vincent Rajkumar · 2022 · 74 citations · Cited by this paper
  27. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments · Massimo Offidani · 2021 · 63 citations · Cited by this paper
  28. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma · Dickran Gano Kazandjian · 2021 · 49 citations · Cited by this paper
  29. Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison · Chiara L. Whichello · 2020 · 47 citations · Cited by this paper
  30. Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study · Rosanne Janssens · 2021 · 44 citations · Cited by this paper
  31. Mode of progression in smoldering multiple myeloma: a study of 406 patients · Nadine H. Abdallah · 2024 · 30 citations · Cited by this paper
  32. Myeloma Patient Value Mapping: A Discrete Choice Experiment on Myeloma Treatment Preferences in the UK · Simon J. Fifer · 2020 · 26 citations · Cited by this paper
  33. Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US · Chiara L. Whichello · 2019 · 21 citations · Cited by this paper
  34. Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial · Omar Nadeem · 2025 · 20 citations · Cited by this paper
  35. Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany · Jianming He · 2021 · 19 citations · Cited by this paper
  36. Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study · Imad Maatouk · 2018 · 18 citations · Cited by this paper
  37. Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions · Agnieszka Blum · 2018 · 16 citations · Cited by this paper
  38. The consultant's guide to smoldering multiple myeloma · Sigrún Þorsteinsdóttir · 2022 · 14 citations · Cited by this paper
  39. Understanding health outcome preferences of older adults diagnosed with multiple myeloma · Supriya Maheshwari · 2024 · 14 citations · Cited by this paper

Source: OpenAlex (CC0)